Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2018 07:30 ET | Source: Iterum Therapeutics plc

Iterum Reports Second Quarter 2018 Financial Results and Recent Highlights

DUBLIN, Ireland and CHICAGO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant...
August 09, 2018 16:05 ET | Source: Iterum Therapeutics plc

Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

First of three planned Phase 3 pivotal trials now underway for Iterum’s oral antibiotic Oral sulopenem, if approved, could be the first antibiotic for uncomplicated urinary tract infections in over...
March 06, 2018 07:30 ET | Source: Otonomy, Inc.

Otonomy to Present at Cowen and Company Health Care Conference

SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that...
March 02, 2018 11:55 ET | Source: Otonomy, Inc.

Otonomy Announces FDA Approval of OTIPRIO(R) for Acute Otitis Externa

SAN DIEGO, March 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that the...
January 09, 2018 07:30 ET | Source: Otonomy, Inc.

Otonomy Provides Corporate and Product Pipeline Update

SAN DIEGO, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for diseases and disorders of the ear,...
January 04, 2018 07:30 ET | Source: Otonomy, Inc.

Otonomy to Present at the J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for diseases and disorders of the ear,...
November 27, 2017 16:30 ET | Source: Otonomy, Inc.

Otonomy Announces Plan to Focus Resources on Development Programs

Company to focus resources on completing OTIVIDEX™ clinical development to support U.S. regulatory approval for Ménière’s disease, and advancing multiple other programs addressing hearing loss and...
November 22, 2017 07:30 ET | Source: Otonomy, Inc.

Otonomy to Present at Piper Jaffray Healthcare Conference

SAN DIEGO, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
November 08, 2017 16:12 ET | Source: Otonomy, Inc.

Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
November 08, 2017 16:05 ET | Source: Otonomy, Inc.

Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménière's Disease

Achieved primary endpoint (p value = 0.029)Company plans to meet with FDA to discuss results and clinical requirements for registrationManagement will review results during third quarter conference...